HEM Pharma Inc
376270
Company Profile
Business description
HEM Pharma Inc is a microbiome-specialized healthcare company that operates a customized healthcare business and an LBP (Live Biotherapeutic Products) discovery platform business utilizing PMAS (Personalized Pharmaceutical Metal-Analytical Screening), a gut microbiome simulation technology. Its technology includes PMAS, MBR, Multi-omics, Microbiome, and Metabolome.
Contact
558, Handong-ro, Heunghae-eup
F102ho, 102ho
Gyeongsangbuk-do
Buk-gu
Pohang-si
KORT: +82 18994258
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
110
Stocks News & Analysis
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
With the monetization of GenAI, here’s what we think of Alphabet’s stock
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,985.10 | 43.60 | 0.49% |
| CAC 40 | 7,744.41 | 53.81 | -0.69% |
| DAX 40 | 24,041.90 | 265.90 | -1.09% |
| Dow JONES (US) | 44,502.44 | 179.37 | 0.40% |
| FTSE 100 | 9,023.81 | 10.82 | 0.12% |
| HKSE | 25,130.03 | 135.89 | 0.54% |
| NASDAQ | 20,892.69 | 81.49 | -0.39% |
| Nikkei 225 | 40,721.17 | 946.25 | 2.38% |
| NZX 50 Index | 12,756.49 | 77.25 | -0.60% |
| S&P 500 | 6,309.62 | 4.02 | 0.06% |
| S&P/ASX 200 | 8,721.50 | 44.30 | 0.51% |
| SSE Composite Index | 3,581.86 | 22.07 | 0.62% |